GLP-1 Receptor Agonists Useful Adjunct in Psoriasis Management, Suggests Study
USA: Emerging evidence indicates that GLP-1 receptor agonists may play a supportive role alongside standard psoriasis therapies. Several studies have reported improvements in disease severity and patient quality of life with these agents. Their benefits seem particularly pronounced in individuals with obesity, where weight reduction may amplify treatment response, positioning GLP-1–based therapies as a promising option for selected patients.
Psoriasis is a chronic immune-mediated condition that extends beyond the skin, often coexisting with a wide range of systemic comorbidities, including cardiovascular disease, metabolic disorders, musculoskeletal conditions, psychiatric illness, and organ-specific complications involving the liver, kidneys, and lungs.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), already approved for conditions such as type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, and metabolic dysfunction–associated steatohepatitis, have gained attention for their potential dual benefits in psoriasis. Given the overlap between psoriasis and these metabolic conditions, these agents are being explored to address both dermatologic and systemic disease components simultaneously.
The review, developed by the Medical Board of the National Psoriasis Foundation and published in JAMA Dermatology, provides an evidence-based overview and practical guidance for dermatologists considering GLP-1 RAs in clinical practice.
Key Findings:
- GLP-1 receptor agonists may improve psoriatic skin disease through combined metabolic and immunomodulatory effects
- Observational studies show reductions in PASI scores, with improvements of approximately 40% to 80%
- Treatment is associated with better patient-reported quality of life
- Benefits extend beyond glycemic control and weight loss
- Agents such as semaglutide and liraglutide reduce inflammatory markers, including C-reactive protein and interleukin-6
- Improvements in lipid profile and reductions in visceral fat have been reported
- Psoriasis improvement may correlate with reduced superficial adiposity and decreased dermal γδ T-cell density
- GLP-1 receptor agonists can be safely combined with methotrexate, cyclosporine, and biologic therapies
- The safety profile is generally favorable, with mostly transient gastrointestinal side effects
- Serious adverse events such as pancreatitis and gallbladder complications are rare but require monitoring
Despite these encouraging findings, the authors emphasize that much of the current evidence is derived from small, short-term studies, often lacking control groups. As a result, while early data support the adjunctive use of GLP-1–based therapies in patients with psoriasis—particularly those with metabolic comorbidities—larger randomized controlled trials are needed to establish definitive efficacy and long-term safety.
Overall, the review highlights the potential of GLP-1 receptor agonists to target both inflammatory and metabolic pathways in psoriasis, offering a more integrated approach to disease management in appropriately selected patients.
Reference:
Sheth S, Merola JF, Weber BN, et al. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review. JAMA Dermatol. Published online April 29, 2026. doi:10.1001/jamadermatol.2026.0859
Next Story